Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063212 · ClinicalTrials.gov registry record · Phase 2
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
A Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT07063212 is a Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07063212, a Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Sacituzumab Govitecan
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2028-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07063212
The ClinicalTrials.gov registry entry for NCT07063212 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (76% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT07063212 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07063212 about?
NCT07063212 is a clinical study titled "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)". The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
What is the current status of trial NCT07063212?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-02. Estimated completion is 2028-01-02.
What conditions does trial NCT07063212 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer, Oropharynx Squamous Cell Carcinoma.
What interventions are being tested in trial NCT07063212?
The interventions under investigation include: Cetuximab (DRUG), Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT07063212?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07063212 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RECRUITING · Phase 2
-
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
RECRUITING · Phase 2
-
Pembrolizumab Plus Olaparib in LA-HNSCC
ACTIVE NOT RECRUITING · Phase 2
-
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
COMPLETED · Phase 2
Explore more on PlainTrial
Squamous Cell Carcinoma of Head and Neck
All registered trials for this condition
Oropharynx Cancer
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.